Ambulatory Blood Pressure Monitoring (ABPM): 2017 ACC/AHA Thresholds, Nocturnal Dipping Phenotypes, FDA 21 CFR 870.1130, and CPT 93784

General clinical research, medical device regulatory, and health informatics reference only; this article does not provide individual medical advice or diagnostic instructions.

Cardiovascular trialists, clinical investigators, and hypertension specialists using ambulatory blood pressure monitoring (ABPM) rely on automated 24-hour out-of-office blood pressure profiling to eliminate observer bias, distinguish white-coat and masked hypertension phenotypes, and quantify circadian blood pressure dynamics. Governed by the 2017 ACC/AHA high blood pressure clinical practice guideline, U.S. Food and Drug Administration (FDA) Class II device regulations (21 CFR 870.1130), and Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) 20.19, ABPM serves as the reference standard for out-of-office hemodynamic assessment in both clinical care and antihypertensive drug development.

What Is Ambulatory Blood Pressure Monitoring and How Is It Used in Clinical Research and Healthcare?

Ambulatory blood pressure monitoring (ABPM) is a noninvasive diagnostic modality in which a portable, automated oscillometric blood pressure recorder and brachial cuff are worn continuously by a patient—typically for 24 to 48 hours—during normal daily activities and nighttime sleep. The recorder is programmed to inflate at fixed intervals: typically every 15 to 30 minutes during daytime (awake) hours and every 30 to 60 minutes during nighttime (asleep) hours.

Unlike single-point clinic readings, which are confounded by alerting reactions and measurement variability, 24-hour ABPM captures 50 to 80 discrete systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and heart rate measurements. In clinical practice and cardiovascular risk assessment (alongside tools such as the ASCVD Risk Estimator), ABPM classifies patients into four diagnostic cross-classifications by pairing clinic BP with 24-hour out-of-office BP:

• Normotension: Normal clinic BP (<130/80 mmHg) and normal ABPM (daytime <130/80 mmHg; 24-hour <125/75 mmHg).
• Sustained Hypertension: Elevated clinic BP (≥130/80 mmHg) confirmed by elevated ABPM averages.
• White-Coat Hypertension: Elevated clinic BP (≥130/80 mmHg) in an untreated patient whose daytime and 24-hour ABPM averages remain below diagnostic hypertension thresholds.
• Masked Hypertension: Normal clinic BP (<130/80 mmHg) paired with elevated daytime (≥130/80 mmHg), nighttime (≥110/65 mmHg), or 24-hour (≥125/75 mmHg) ABPM readings—a phenotype associated with cardiovascular target-organ risk comparable to sustained hypertension.

2017 ACC/AHA Guideline Blood Pressure Equivalency Thresholds

The 2017 ACC/AHA hypertension guideline establishes the following corresponding blood pressure levels connecting office measurements to 24-hour ABPM averages:

Clinic (Office) BP Category (mmHg)	Daytime (Awake) ABPM Mean (mmHg)	Nighttime (Asleep) ABPM Mean (mmHg)	24-Hour Total ABPM Mean (mmHg)
120/80 (Elevated BP threshold)	120/80	100/65	115/75
130/80 (Stage 1 Hypertension threshold)	130/80	110/65	125/75
140/90 (Stage 2 Hypertension threshold)	135/85	120/70	130/80
160/100 (Severe Hypertension)	145/90	140/85	145/90

Note: International guidelines (such as the European Society of Cardiology / European Society of Hypertension [ESC/ESH] guidelines) historically reference a clinic threshold of ≥140/90 mmHg, which corresponds to the row of ≥130/80 mmHg (24-hour mean), ≥135/85 mmHg (daytime mean), and ≥120/70 mmHg (nighttime mean).

Nocturnal Dipping Phenotypes in Clinical Research

A unique advantage of ambulatory blood pressure monitoring in clinical research over daytime home blood pressure monitoring is its ability to measure sleep blood pressure and the nocturnal dipping percentage, calculated as:

Nocturnal Dip (%) = [(Daytime Mean BP − Nighttime Mean BP) / Daytime Mean BP] × 100

• Normal Dipper (10% to 20% nocturnal drop): Physiological circadian reduction in sympathetic tone during sleep.
• Non-Dipper (0% to <10% nocturnal drop): Blunted nocturnal fall, strongly associated with obstructive sleep apnea, chronic kidney disease, diabetic autonomic neuropathy, and elevated left ventricular hypertrophy risk.
• Reverse Dipper / Riser (<0% drop; nighttime BP exceeds daytime BP): Carries the highest independent hazard ratio for stroke, heart failure hospitalization, and cardiovascular mortality.
• Extreme Dipper (>20% nocturnal drop): Associated in older cohorts with silent cerebrovascular ischemia and morning blood pressure surge events.

What Standards or Regulatory Requirements Govern Ambulatory Blood Pressure Monitoring?

Hardware validation, clinical trial execution, and reimbursement for ABPM are governed by three regulatory frameworks:

1. FDA Device Classification (21 CFR 870.1130) and ISO 81060-2 Validation: Under U.S. Food and Drug Administration regulations, noninvasive blood pressure measurement systems (including automated ABPM recorders, FDA product code DXN) are Class II medical devices requiring premarket notification (510(k)). Clinical accuracy validation is evaluated against consensus standard ANSI/AAMI/ISO 81060-2, which requires not only static resting accuracy (mean error ≤ ±5.0 mmHg with standard deviation ≤ 8.0 mmHg against reference auscultation) but also an additional ambulatory validation study in ≥35 hypertensive subjects during heart rate elevation after physical exercise. Researchers can cross-check validated blood pressure monitors on peer-reviewed registries such as the US Blood Pressure Validated Device Listing (VDL) or STRIDE BP.
2. Antihypertensive Drug Trial Regulatory Design: In FDA Center for Drug Evaluation and Research (CDER) cardiovascular drug trials, 24-hour ABPM is used to establish the trough-to-peak ratio and verify that a once-daily antihypertensive formulation maintains blood pressure reduction across the full 24-hour dosing interval (particularly during the early-morning surge window between 06:00 and 10:00), while minimizing placebo effect and reducing required sample sizes compared with office sphygmomanometry.
3. CMS National Coverage Determination (NCD 20.19) and CPT Coding: Under CMS NCD 20.19 (see also Medicare blood pressure monitor coverage), Medicare covers 24-hour ABPM once per year for beneficiaries with suspected white-coat hypertension or suspected masked hypertension. Standard Current Procedural Terminology (CPT) codes are:
   • CPT 93784: Global 24-hour or longer ABPM service, including recording, scanning analysis, physician review and interpretation, and written report.
   • CPT 93786: Recording only (hook-up and device retrieval).
   • CPT 93788: Technical scanning analysis with report.
   • CPT 93790: Physician review, interpretation, and written report only.

   For a 24-hour ABPM recording to be considered technically valid for research and clinical reporting, consensus guidelines generally require at least 70% successful inflation readings across the 24-hour window (typically ≥20 valid daytime and ≥7 valid nighttime readings).

How Does Ambulatory Blood Pressure Monitoring Integrate with EHR and Health Informatics Workflows?

Similar to continuous physiologic telemetry such as Continuous Glucose Monitoring (CGM), modern ABPM devices transfer time-series arrays into EHRs and clinical trial Electronic Data Capture (EDC) platforms using structured interoperability standards:

• LOINC and HL7 FHIR R4 Observation Mapping: Rather than filing only a static PDF summary scan, informatics pipelines map aggregate and discrete ABPM metrics to standardized LOINC codes inside HL7 FHIR Observation and DiagnosticReport resources—including 24-hour mean systolic BP (LOINC 8491-3), 24-hour mean diastolic BP (LOINC 8466-5), daytime mean systolic/diastolic BP, and asleep mean systolic/diastolic BP—accompanied by SNOMED CT body site (left/right brachial artery) and cuff size qualifiers.
• CDISC SDTM Clinical Trial Submissions: In regulated pharmaceutical trials, individual timestamped ABPM readings and derived window means are mapped to the CDISC Study Data Tabulation Model (SDTM) Vital Signs (VS) domain (using VSTESTCD values for systolic/diastolic BP and VSTPT / VSELTM timepoint variables) and analyzed in the Analysis Data Model (ADaM) ADVS dataset.